What are the side effects of Vebreltinib?

Vebreltinib is a new type of targeted small molecule inhibitor that mainly blocks cancer cell proliferation, survival and migration signaling pathways by inhibiting c-Met receptor kinase activity. It is effective in treating MET exon 14 It has shown potential in jump mutation non-small cell lung cancer (NSCLC) and certain brain tumors related to the PTPRZ1-MET fusion gene. Although boricitinib has high targeting, it is still accompanied by certain drug-related side effects in clinical application. Most of these side effects are controllable and monitorable events, which require the joint attention of patients and medical staff.

In clinical observations, the most common side effects of bricitinib include digestive system reactions, such as mild to moderate nausea, decreased appetite, diarrhea, or constipation. These symptoms are related to the effects of drugs on the gastrointestinal mucosa and neural regulation, but in most cases they can be alleviated through symptomatic treatment or dose adjustment. Some patients may experience fatigue, weakness, or mild dizziness, which is the result of a combination of systemic metabolic responses and targeted signal inhibition.

In addition, bricitinib may cause cardiovascular-related events, such as blood pressure fluctuations or mild heart palpitations. A small number of patients may develop liver function abnormalities, including elevated transaminases, which are due to the mild effects of the drug on hepatocytes during hepatic metabolism. Therefore, periodic electrocardiogram and liver function monitoring are required during treatment. Skin reactions are relatively mild and may manifest as rash or itching, and generally do not affect the continuity of treatment.

Overall, the side effects of bricitinib are mostly controllable and monitorable, and usually do not cause serious irreversible damage. Through dose adjustment, symptomatic treatment, and close communication between doctors and patients, most patients can continue to receive treatment safely. Compared with traditional chemotherapy, buricitinib has strong targeting and relatively mild side effects, making it highly clinically valuable in targeted cancer treatment.

Reference materials:https://www.asymbio.com.cn/